Patents Assigned to JCR Pharmaceuticals Co., Ltd.
-
Publication number: 20210301258Abstract: The present disclosure relates to a method for producing dental pulp-derived cells enriched with pluripotent stem cells including: (a) digesting dental pulp with a protease to prepare a dental pulp suspension; (b) culturing the suspension to proliferate pluripotent stem cells contained in the suspension; (c) freezing the proliferated pluripotent stem cells in a state in which the pluripotent stem cells are suspended in a first cryopreservation liquid; (d) thawing the frozen pluripotent stem cells; (e) culturing the thawed pluripotent stem cells in a state in which the pluripotent stem cells are adhered to surfaces of particles to proliferate the pluripotent stem cells on the surfaces of the particles; and (f) bringing the particles into contact with a protease to separate the pluripotent stem cells adhered to the surfaces of the particles from the particles.Type: ApplicationFiled: July 30, 2019Publication date: September 30, 2021Applicants: JCR Pharmaceuticals Co., Ltd., Teijin LimitedInventors: Kiwamu Imagawa, Kotaro Minami, Kenichi Maeda, Yuki Hosoda, Shunsuke Watanabe, Kazutoshi Sato, Yasuna Higashiguchi, Takashi Kushida, Ayumi Ishiwari
-
Patent number: 11130815Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.Type: GrantFiled: June 24, 2016Date of Patent: September 28, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11111308Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: June 23, 2020Date of Patent: September 7, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20210269543Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: May 17, 2021Publication date: September 2, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20210252112Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.Type: ApplicationFiled: June 25, 2019Publication date: August 19, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hidehito YASUKAWA, Takashi HANADA, Junya TANI, Shinji OKABE, Yuuka ASANO
-
Patent number: 11078293Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: June 23, 2020Date of Patent: August 3, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11046751Abstract: Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.Type: GrantFiled: April 10, 2020Date of Patent: June 29, 2021Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Kenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
-
Publication number: 20210187082Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.Type: ApplicationFiled: February 22, 2021Publication date: June 24, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
-
Publication number: 20210171561Abstract: Disclosed is a method for decomposing chondroitin sulfate contained in a sample into disaccharide. In particular disclosed is a method for decomposing chondroitin sulfate contained in a sample into disaccharide by heating the chondroitin sulfate in HCl-methanol containing 2,2-dimethoxypropane at a temperature of 60° C. to 90° C. for 50 minutes to 180 minutes, optionally in the method, the sample is selected from body fluid, a cell, a tissue, an organ, a cell culture solution, a tissue culture solution, a food, and a feed, or a derived therefrom.Type: ApplicationFiled: February 22, 2021Publication date: June 10, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Noboru TANAKA, Sachiho KIDA
-
Publication number: 20210132040Abstract: A method for decomposing dermatan sulfate and heparan sulfate contained in a sample into a disaccharide, respectively, wherein the dermatan sulfate is decomposed into a disaccharide in which a uronic acid and an amino sugar are joined with an ?-1,3 bond, and the heparan sulfate is decomposed into the disaccharide in which the uronic acid and the amino sugar are joined with the ?-1,4 bond, and wherein, the dermatane sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, at a temperature of 60 to 80° C., and for 20 to 100 minutes, and the heparan sulfate is decomposed by heating in hydrogen chloride methanol solution containing 2,2-dimethoxypropane, for 80 to 180 minutes, and at a temperature of 65 to 85° C.Type: ApplicationFiled: February 20, 2018Publication date: May 6, 2021Applicant: JCR PHARMACEUTICALS CO., LTD.Inventors: Noboru TANAKA, Sachiho KIDA
-
Publication number: 20210104046Abstract: Disclosed are a software for analyzing images of a fertilized egg, the software providing a means for executing a process including: (a) a step of measuring the difference in area between the female pronucleus and the male pronucleus from images of a fertilized egg obtained in a period of 1 to 10 hours before the time of occurrence of male and female pronuclear membrane breakdown as a reference; (b) a step of measuring the difference in are between the female pronucleus and the male pronucleus from images of the fertilized egg obtained immediately before the time of occurrence of male and female pronuclear membrane breakdown as the reference; and (c) a step of storing the measured values of the area difference obtained in the step (a) and the area difference obtained in the step (b), to be readable at any time as needed, and an apparatus incorporating this software.Type: ApplicationFiled: December 17, 2020Publication date: April 8, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Masahide SHIOTANI, Junko OTSUKI
-
Patent number: 10968267Abstract: Disclosed is a medicine containing a long-lasting human growth hormone preparation as an active ingredient, which has low prolactin-like activity and shows long half-life in blood as compared with 22K human growth hormone. The long-lasting human growth hormone includes a fusion protein exhibiting growth-promoting activity and having a human serum albumin part and a 20K human growth hormone part, particularly a fusion protein in which the 20K human growth hormone part is linked to C-terminus of the human serum albumin part via a linker sequence.Type: GrantFiled: September 14, 2018Date of Patent: April 6, 2021Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Kenichi Takahashi, Aya Yoshioka, Yuri Koshimura
-
Patent number: 10940185Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.Type: GrantFiled: December 28, 2017Date of Patent: March 9, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
-
Publication number: 20210061918Abstract: Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.Type: ApplicationFiled: September 7, 2018Publication date: March 4, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hidehito YASUKAWA, Yuka YAMAGUCHI, Shinji OKABE
-
Publication number: 20210038739Abstract: [Problems] To provide a technique for efficiently incorporating an agent having to function in muscle tissue, which is not sufficiently incorporated into muscle tissue when administered in body, into muscle tissue, particularly muscle tissue composed of skeletal muscle or cardiac muscle. [Solution] A conjugate of an anti-human transferrin receptor antibody and an agent, wherein the agent is a biologically active agent that should function in muscle tissue, e.g., a lysosomal enzyme such as acid ?-glucosidase, ?-galactosidase A.Type: ApplicationFiled: February 5, 2019Publication date: February 11, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Kenichi Takahashi, Hiroyuki Sonoda
-
Publication number: 20200406229Abstract: A chromatography column for the use of separation of acidic sugar chains, wherein the column comprises a first column and a second column, the second column connected by a flow path downstream of an outlet of the first column, and selected from the following (1) or (2): (1) the carrier of the first column is hydrophobically modified silica having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine; (2) the carrier of the first column is a resin having a group containing a primary amine, a secondary amine or/and a tertiary amine, and the carrier of the second column is hydrophobically modified silica having a group containing a primary amine, a secondary amine, or/and a tertiary amine.Type: ApplicationFiled: November 14, 2018Publication date: December 31, 2020Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Tomoki FUKATSU, Chika MOROOKA
-
Publication number: 20200384061Abstract: The present invention provides a fusion protein of BDNF and an anti-human transferrin receptor antibody, in which in a heavy chain variable region of the antibody, (a) CDR1 includes an amino acid sequence of SEQ ID NO: 66 or SEQ ID NO: 67, (b) CDR2 includes an amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 includes an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16.Type: ApplicationFiled: December 26, 2017Publication date: December 10, 2020Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 10858640Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.Type: GrantFiled: April 28, 2017Date of Patent: December 8, 2020Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
-
Publication number: 20200317798Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: June 23, 2020Publication date: October 8, 2020Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 10759864Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: December 26, 2017Date of Patent: September 1, 2020Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi